Search

Displaying results 2781 - 2790 of 10000 in total
  1. Drug

    Rubella virus vaccine

    go.drugbank.com/drugs/DB10317
    ApprovedInvestigational

    It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus). … Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered.

    Synonyms: Rubella virus live antigen, A, Rubivirus rubella virus Wistar RA 27/3 whole
  2. Drug

    Kanamycin

    go.drugbank.com/drugs/DB01172
    ApprovedInvestigationalVet approvedWithdrawn

    Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.

    Synonyms: Kanamycin ACategories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
  3. Drug

    Orciprenaline

    go.drugbank.com/drugs/DB00816
    Approved

    A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]

  4. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. … It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile.

  5. Drug

    Subasumstat

    go.drugbank.com/drugs/DB16406
    Investigational

    or Metastatic Solid Tumors or Relapsed/refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)). … Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced

  6. Drug

    Maraviroc

    go.drugbank.com/drugs/DB04835
    ApprovedInvestigational

    Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the

  7. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP).

  8. Drug

    Avutometinib

    go.drugbank.com/drugs/DB15254
    ApprovedInvestigational

    Avutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. … [L53203,L53198] The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, differentiation and survival.

    Synonyms: N-(3-fluoro-4-((4-methyl-2-oxo-7-((pyrimidin-2-yl)oxy)-2H-1-benzopyran-3-yl)methyl)pyridin-2-yl)-N'-methylsulfuric diamide, Sulfamide, N-(3-fluoro-4-((4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-1-benzopyran-3-yl)methyl)-2-pyridinyl)-N'-methyl-
  9. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that … It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical

  10. Drug

    QXL138AM

    go.drugbank.com/drugs/DB18552
    Investigational

    QXL138AM is a masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a. It binds the CD138 protein on the surface of the tumour cells.

    Synonyms: Masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a